静脉注射重组人脑钠利肽在慢性中重度心力衰竭失代偿期的疗效研究被引量：2

The Research about Effects of Intravenous Recombinant Human Brain Natriuretic Peptide in Patients with Chronic Moderate and Severe Decompensated Heart Failure

暂未订购

导出

摘要目的:前瞻性对比研究利尿、扩血管等常规抗心衰治疗与加用静脉注射重组BNP(rhBNP)治疗在慢性中重度心力衰竭失代偿期的疗效。方法:选自2008年4月～2009年4月于我院心内科住院的慢性中重度失代偿性心力衰竭病人40人,分为常规治疗组(如利尿剂、ACEI、硝普钠、多巴胺、多巴酚丁胺等治疗)和加用rhBNP组(负荷剂量1.5ug/kg静脉注射,随后以0.01ug/kg·min持续静滴48小时)两个组。每组20例。比较两组的治疗前后的NT-proBNP下降程度。结果:加用rhBNP组的NT-proBNP 下降程度高于常规治疗组,有统计学意义。结论:对于慢性中重度心力衰竭失代偿期的患者,在常规抗心衰治疗基础上加用rhBNP可更好的改善心功能。 Objective：To prospectively compare the effects of conventional therapy, including diuretic, vasodilator and so on,versus intravenous recombinant BNP additionally in patients with chronic moderate and severe deeompensated heart failure. Methods：40 patients with chronic moderate and severe heart decompensated failure were randomized into conventional therapy group（n=20, including diuretic, ACE inhibitor, sodium nitroprusside, doparnine, dobutamine and so on）and intravenous rBNP additionally group（n=20, 1.5ug/kg intravenous injection,following by 0.01ug/kg.min for 48 hours） form April in 2008 to April in 2009. The decrease degree of amino-terminal pro-B-type natriuretic peptide between before and after therapy were compared in two groups. Results：The decrease degree of NT-proBNP in the intravenous rBNP additionally group is more than the conventional therapy（P〈0.01）.Conclusion： Intravenous rBNP additionally in patients with chronic moderate and severe decompensated heart failure could be more better in improving heart function on the basis of conventional therapy.

作者陈新丁志坚王新

机构地区南京医科大学附属常州市第二人民医院心内科

出处《中国医药导刊》 2010年第6期971-973,共3页 Chinese Journal of Medicinal Guide

关键词 RHBNP NT-PROBNP 慢性中重度心力衰竭失代偿期疗效 rhBNP NT-proBNP Chronic moderate and severe decompensated heart failure Effect

分类号 R473.75 [医药卫生—护理学]

引文网络
相关文献

参考文献19

1FDA,Guidance for industry,non-inferiority clinclal trials.www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM202140.pdf,2010.
2Kragelund C,Gronning B Kober L,Hildebrandt p,et al.N-Terminal Pro-B-Type Natriurctic Peptide and Long-term Mortality in Stable Coronary Heart Diease.N Engl J Med,2005;352:666-675.
3Januzzi JL,Kimmanade R,Lainchhury J,et al.NT-proBNP testing for diagnosis and short-term prognosisi in acute destabilized heart failure:an intcmatonal pooled analysisi of 1256 patients.European Heart Journa,2006; 27:330-337.
4Dhaliwal AS,Deswal A,Pritchett A,et al.Reduction in BNP levels with treatment of decompensated heart failure and future clinical events.J Card Fail.2009 May; 15(4):293-299.
5Muller T,Gegenhuber A,Dieplinger BA,et al.Longterm stability of endogenous B-type natriuretic peptide(BNP) and amino terminal proBNP(NT-proBNP)in frozen plasma samples.Clio Chera Lab Meal,2004; 42(8):942-944.
6Peacock WF,Emerman CL,Silver MA.Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute dccompensated heart failure[J].Am J Emerg Med,2005;23:327-331.
7Burger A J,Horten DP,LeJemtel T,et al.Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment patients with acutely decompensated congestive heart failure:The PRECEDENT Study[J].Am Heart J,2002;144:1102-1108.
8Colucci WS,Elkayam U,Horton DP,et al.Intravenous nesiritide,anatriuretic peptide,in the treatment of decompensated congestive heart failure[J].N Engl J Med,2000;343:246-253.
9Clyde W,Mitchell T,Robert L,et al.Safety and Feasibility of Using Serial Infusions of Nesiritide for Heart Failure in an Outpatient Setting (from the FUSION I Trial).Am J Cardiol,2004;94;595-601.
10Yancy CW.Nesiritide is safe for CHF patients with renal insufficiency:retrospective results from the follow2up serial infusions of ansiritide (FUSION)Trial[J].J Card Fail,2004;10 (suppl):S114.